In a recent meta-analysis, Dafonte et al. highlighted that the assessment of the correct dose for patients with liver cirrhosis is conditioned by various patient-related factors, including increased body fluid levels, disturbed electrolyte balance, reduced serum albumin and other protein levels, decreased muscle mass, presence of portosystemic shunts, and impaired hepatic metabolism with a diminished first-pass effect. The gene discussed is ALB; the disease is cirrhosis of liver.